(MENAFN- EIN Presswire) Enzyme Replacement Therapy Industry
The Booming Enzyme Replacement Therapy Market with Cutting-Edge Innovations and Promising Treatment Options
PORTLAND, OREGON, UNITED STATES, April 24, 2023 /einpresswire.com / -- Enzyme Replacement Therapy (ERT) has emerged as a promising treatment option for various enzyme deficiency disorders. These disorders, also known as lysosomal storage disorders (LSDs), result from a deficiency of specific enzymes required for proper cellular metabolism. ERT involves administering exogenous enzymes to replace or supplement the deficient enzymes, thereby addressing the underlying cause of the disorder.
The global enzyme replacement therapy market has been witnessing significant growth in recent years. In 2020, the market was valued at $7,780.69 million, and it is projected to reach $15,166.34 million by 2030, with a compound annual growth rate (CAGR) of 8.3% from 2021 to 2030.
Several factors are driving the growth of the enzyme replacement therapy market. One of the key drivers is the increasing prevalence of enzyme deficiency disorders, including Gaucher disease, Fabry disease, Pompe disease, and others. These rare genetic disorders often result in severe morbidity and mortality if left untreated, creating a high demand for effective treatment options like ERT.
Inquiry Before Purchase:
Key Market Players
1.Abbvie Inc.
2.Astrazeneca Plc
3.Biomarin Pharmaceutical In
4.Chiesi Farmaceutici S.P.A.
5.Digestive Care, Inc.
6.Leadiant Biosciences, Inc.
7.Nestle Health Science
8.Pfizer Inc.
9.Sanofi
10.Takeda Pharmaceuticals
Enzyme Replacement Therapy Market Report Highlights
Product:
.Agalsidase Beta: Agalsidase beta is an enzyme replacement therapy used for the treatment of Fabry disease, a rare genetic disorder caused by the deficiency of an enzyme called alpha-galactosidase A. Agalsidase beta is administered intravenously and helps to reduce the accumulation of globotriaosylceramide (GL-3) in various organs and tissues.
.Imiglucerase: Imiglucerase is an enzyme replacement therapy used for the treatment of Gaucher disease, a rare genetic disorder caused by the deficiency of an enzyme called glucocerebrosidase. Imiglucerase is administered intravenously and helps to reduce the accumulation of glucocerebroside in various organs and tissues.
.Velaglucerase Alfa: Velaglucerase alfa is an enzyme replacement therapy used for the treatment of Gaucher disease, similar to imiglucerase. Velaglucerase alfa is administered intravenously and helps to reduce the accumulation of glucocerebroside in various organs and tissues.
.Idursulfase: Idursulfase is an enzyme replacement therapy used for the treatment of Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), a rare genetic disorder caused by the deficiency of an enzyme called iduronate-2-sulfatase. Idursulfase is administered intravenously and helps to break down the accumulation of glycosaminoglycans (GAGs) in various organs and tissues.
.Galsulfase: Galsulfase is an enzyme replacement therapy used for the treatment of Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), a rare genetic disorder caused by the deficiency of an enzyme called N-acetylgalactosamine-4-sulfatase. Galsulfase is administered intravenously and helps to break down the accumulation of GAGs in various organs and tissues.
.Laronidase: Laronidase is an enzyme replacement therapy used for the treatment of Hurler syndrome, also known as mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by the deficiency of an enzyme called alpha-L-iduronidase. Laronidase is administered intravenously and helps to break down the accumulation of GAGs in various organs and tissues.
.Others: There are several other enzyme replacement therapies available for the treatment of rare genetic disorders caused by enzyme deficiencies, such as asfotase alfa for hypophosphatasia, alglucosidase alfa for Pompe disease, and lipase for exocrine pancreatic insufficiency (EPI), among others.
Disease:
.Gaucher Disease: Gaucher disease is a rare genetic disorder caused by the deficiency of glucocerebrosidase enzyme, leading to the accumulation of glucocerebroside in various organs and tissues. ERTs such as imiglucerase and velaglucerase alfa are used for the treatment of Gaucher disease.
.Fabry Disease: Fabry disease is a rare genetic disorder caused by the deficiency of alpha-galactosidase A enzyme, leading to the accumulation of globotriaosylceramide (GL-3) in various organs and tissues. Agalsidase beta is used for the treatment of Fabry disease.
.Pompe Disease:
FREQUENTLY ASKED QUESTIONS?
1.What is Enzyme Replacement Therapy (ERT) and how does it work?
2.What are the common conditions or diseases that can be treated with Enzyme Replacement Therapy?
3.What are the benefits and limitations of Enzyme Replacement Therapy in the treatment of certain diseases or conditions?
4.What are the different types of Enzyme Replacement Therapy available in the market?
5.How is Enzyme Replacement Therapy administered and what are the potential side effects?
6.What are the key factors driving the growth of the Enzyme Replacement Therapy market globally?
7.What are the major challenges or barriers faced by the Enzyme Replacement Therapy market?
8.What are the current trends and advancements in Enzyme Replacement Therapy research and development?
9.How does Enzyme Replacement Therapy compare to other treatment options for the same conditions or diseases?
10.What is the current and projected market size of the Enzyme Replacement Therapy market, and what are the key market players and their strategies?
Buy Premium Copy of Enzyme Replacement Therapy Market Growth Report at:
Browse other research published by Allied Market Research:
Ophthalmic Knives Market -
Over The Counter (OTC) Test Market -
Snared Devices Market -
Telmisartan Market -
Neurodegenerative Drugs Market -
Obesity Intervention Devices Market -
David Correa
Allied Analytics LLP
+1-800-792-5285
email us here
Comments
No comment